Navigation Links
Pharma IQ's Drug Recalls Industry Outline
Date:8/24/2012

LONDON, August 24, 2012 /PRNewswire/ --

Pharma IQ has just produced the Drug Recalls Industry Outline, where it analyses the challenges and implications of the late stage development failures. Pharma IQ had a quick look back over the last few years to see a timeline of drug failures and recalls at the late stages of development.

'Some of the key time saving strategies and information sources to make these decisions are trial design approaches, imaging techniques, biomarkers, strategic outsourcing and patient recruitment' says Nicola Ambler, Senior Conference Director, Pharma IQ, who is directing the upcoming Innovation in Phase 1 Clinical Development in Milan this September.

The outline analyses the drug withdrawals in the latter stages. In August 2012, Pfizer and J&J announced they were going to stop the development of the Alzheimer's drug, Bapineuzumab.  In March 2012 AstraZeneca and Targacept announced that their partnered depression drug - TC-5214 - failed at Phase III. The last two of four late-stage studies failed to meet their primary endpoints, eliminating plans for a comeback after the first two Phase III studies also ended in failure. In March 2011 Sanofi-Aventis' lung cancer drug aflibercept failed to meet its primary endpoint in a phase III trial.

The Drug Recalls Industry Outline can be accessed at http://www.phase1clinicaldevelopment.com/news

The Industry Outline was created as a part of the pre-conference preparation for the 3th Innovation in Phase I Clinical Development Forum taking place 17-19 September, 2012 in Milan. The agenda and final speaker line-up feature JW McBlane, Pharmaceutical Assessor, MHRA that will lead the session Early Clinical Studies - A Regulator's Expectations for Complex Protocols and Complex Productsand  Corina Dota, ECG Centre Director, Co-chair Cardiac QT/Arrhythmia Safety Knowledge Group from AstraZeneca presenting the case study Designing and Integrating a Robust Cardiac Safety Strategy.

Other important topics that will be discussed at the event include:

  • Biomarker development and early strategies for patients selection (case study from Roche);
  • Overcoming the internal and external challenges of developing the right biomarker at the right time (open discussion with Lundbeck);
  • Potential impact of ICH guidelines (M3, S9 and S6) on the scientific based non clinical assessment to achieve faster regulatory decisions on anticancer Phase One Clinical Trials (Italian Health Ministry)

To access the full Overview or to find out more about Phase I Clinical Development Forum 2012 please visit http://www.phase1clinicaldevelopment.com/news, email  enquire@iqpc.co.uk or call +44(0)2073689421.

Press are invited to attend this important industry forum, if you would like to a complimentary press pass please email Joanna Checinska (joanna.checinska@iqpc.co.uk)

Media contact: Joanna, +44(0)20-7368-9421, joanna.checinska@iqpc.co.uk  - Please contact for more information or images.


'/>"/>
SOURCE Pharma IQ
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
6. Academy of Managed Care Pharmacy (AMCP) Installs 2012-2013 Board of Directors
7. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
8. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
9. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
10. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
11. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/14/2019)... ... , ... Corey Stern , a partner at Levy Konigsberg, LLP, now ... over at least 3 decades while employed by Rockefeller University Hospital (“RUH”). Stern has ... Southern District of New York, No. 1:19-cv-01403), the first case filed against the University. ...
(Date:9/14/2019)... SARASOTA, Fla. (PRWEB) , ... September 14, 2019 ... ... board review and continuing medical education (CME) courses, is announcing its attempt at ... PA professionals the opportunity to prepare for the PANRE while earning 30 CME ...
(Date:9/12/2019)... ... September 12, 2019 , ... As ... the services of CPESN’s clinically integrated network of more than 2,400 pharmacy locations ... participating pharmacies provide high quality clinical service programs that will now be accessible ...
Breaking Medicine Technology:
(Date:9/11/2019)... , ... September 10, 2019 , ... Women’s Excellence is ... office is location at 32686 Woodward Ave, Suite 103, Royal Oak, MI 48073 in ... Royal Oak location offers comprehensive women’s health services in a contemporary, spa-like atmosphere. ...
(Date:9/11/2019)... NEW YORK (PRWEB) , ... ... ... expertise of industry leaders to explore solutions to problems facing the ever-changing ... edition of their campaign, “Employee Benefits and Engagement.” With topics ranging from ...
(Date:9/9/2019)... ... 2019 , ... ST Engineering iDirect, a company of ST ... iQ 200 Board and the latest Evolution® software release, iDX 4.1.3, into its ... 200 Board will enable the HARRIER solution to achieve higher throughput and greater ...
(Date:9/9/2019)... ... 2019 , ... Cardinal Park Family Dental Care is proud to be a ... family dentistry , laser gum disease treatment, full mouth reconstruction, and dental implants ... Cardinal Park Family Dental Care has provided state-of-the-art, comprehensive dental care for patients in ...
(Date:9/9/2019)... ... September 09, 2019 , ... ... the Upper East Side in Manhattan, New York announced today the addition ... orthodontic division specializes in the orthodontic needs for children including early preventative ...
Breaking Medicine News(10 mins):